These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 32326457)
1. Comparative Kinetics of Acetyl- and Butyryl-Cholinesterase Inhibition by Green Tea Catechins|Relevance to the Symptomatic Treatment of Alzheimer's Disease. Okello EJ; Mather J Nutrients; 2020 Apr; 12(4):. PubMed ID: 32326457 [TBL] [Abstract][Full Text] [Related]
2. In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer's Disease Treatment. Ali B; Jamal QM; Shams S; Al-Wabel NA; Siddiqui MU; Alzohairy MA; Al Karaawi MA; Kesari KK; Mushtaq G; Kamal MA CNS Neurol Disord Drug Targets; 2016; 15(5):624-8. PubMed ID: 26996169 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443 [TBL] [Abstract][Full Text] [Related]
4. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713 [TBL] [Abstract][Full Text] [Related]
5. Molecular insights into the differences in anti-inflammatory activities of green tea catechins on IL-1β signaling in rheumatoid arthritis synovial fibroblasts. Fechtner S; Singh A; Chourasia M; Ahmed S Toxicol Appl Pharmacol; 2017 Aug; 329():112-120. PubMed ID: 28532672 [TBL] [Abstract][Full Text] [Related]
6. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of Aβ aggregates in Alzheimer's disease by epigallocatechin and epicatechin-3-gallate from green tea. Chen T; Yang Y; Zhu S; Lu Y; Zhu L; Wang Y; Wang X Bioorg Chem; 2020 Dec; 105():104382. PubMed ID: 33137558 [TBL] [Abstract][Full Text] [Related]
8. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Lane RM; Potkin SG; Enz A Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515 [TBL] [Abstract][Full Text] [Related]
9. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Greig NH; Lahiri DK; Sambamurti K Int Psychogeriatr; 2002; 14 Suppl 1():77-91. PubMed ID: 12636181 [TBL] [Abstract][Full Text] [Related]
10. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Chow HH; Cai Y; Alberts DS; Hakim I; Dorr R; Shahi F; Crowell JA; Yang CS; Hara Y Cancer Epidemiol Biomarkers Prev; 2001 Jan; 10(1):53-8. PubMed ID: 11205489 [TBL] [Abstract][Full Text] [Related]
11. Green tea polyphenol (-)-epigallocatechin-3-gallate enhances the inhibitory effect of huperzine A on acetylcholinesterase by increasing the affinity with serum albumin. Zhang L; Cao H; Wen J; Xu M Nutr Neurosci; 2009 Aug; 12(4):142-8. PubMed ID: 19622237 [TBL] [Abstract][Full Text] [Related]
12. Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study. Mazumder MK; Choudhury S Med Hypotheses; 2019 Apr; 125():94-99. PubMed ID: 30902161 [TBL] [Abstract][Full Text] [Related]
13. Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases. Gonçalves PB; Sodero ACR; Cordeiro Y Biomolecules; 2021 May; 11(5):. PubMed ID: 34065606 [TBL] [Abstract][Full Text] [Related]
14. Epicatechin gallate and catechin gallate are superior to epigallocatechin gallate in growth suppression and anti-inflammatory activities in pancreatic tumor cells. Kürbitz C; Heise D; Redmer T; Goumas F; Arlt A; Lemke J; Rimbach G; Kalthoff H; Trauzold A Cancer Sci; 2011 Apr; 102(4):728-34. PubMed ID: 21241417 [TBL] [Abstract][Full Text] [Related]
15. Synthesis, pharmacology and molecular docking on multifunctional tacrine-ferulic acid hybrids as cholinesterase inhibitors against Alzheimer's disease. Zhu J; Yang H; Chen Y; Lin H; Li Q; Mo J; Bian Y; Pei Y; Sun H J Enzyme Inhib Med Chem; 2018 Dec; 33(1):496-506. PubMed ID: 29405075 [TBL] [Abstract][Full Text] [Related]
16. Tea catechin synergies in inhibition of cancer cell proliferation and of a cancer specific cell surface oxidase (ECTO-NOX). Morré DJ; Morré DM; Sun H; Cooper R; Chang J; Janle EM Pharmacol Toxicol; 2003 May; 92(5):234-41. PubMed ID: 12753411 [TBL] [Abstract][Full Text] [Related]
17. The green tea catechins, (-)-Epigallocatechin-3-gallate (EGCG) and (-)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells. Bigelow RL; Cardelli JA Oncogene; 2006 Mar; 25(13):1922-30. PubMed ID: 16449979 [TBL] [Abstract][Full Text] [Related]
18. Cholinesterase inhibition in Alzheimer's disease: is specificity the answer? Macdonald IR; Rockwood K; Martin E; Darvesh S J Alzheimers Dis; 2014; 42(2):379-84. PubMed ID: 24898642 [TBL] [Abstract][Full Text] [Related]
19. Green tea catechins evoke a phasic contraction in rat aorta via H2O2-mediated multiple-signalling pathways. Shen JZ; Zheng XF; Wei EQ; Kwan CY Clin Exp Pharmacol Physiol; 2003; 30(1-2):88-95. PubMed ID: 12542460 [TBL] [Abstract][Full Text] [Related]
20. Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Nexus of Cholinergic and Nerve Growth Factor Dysfunction. Moss DE; Perez RG Curr Alzheimer Res; 2021; 18(13):1010-1022. PubMed ID: 34911424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]